Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, ...
Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial Patients with stage III to IV or recurrent, radiographically ...
Intravenous administration of AAVrh.10hFXN, an adeno-associated virus vector encoding normal human frataxin, was associated with reductions in left ventricular mass index (LVMI) and high-sensitivity ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline ...
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial In this global phase III ...
The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear. We conducted a meta-analysis at the individual-patient level ...
Despite guideline recommendations, evidence for the use of non–vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with atrial fibrillation after implantation of a drug-eluting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results